A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

N/ARecruitingNCT06793709

Eisai Co., Ltd.60 enrolled

Overview

The primary purpose of this study is to investigate the safety of Tasfygo.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Biliary Tract Cancer

Interventions

No InterventionOTHER

This is a non-interventional study.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1\. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy. Exclusion Criteria: Not applicable.

Locations (1)

#Eisai Trial Site 1

Tokyo, Japan

RECRUITING

Outcomes

Primary Outcomes

Number of Participants With Adverse Drug Reactions

Time frame: Up to 1 year

Secondary Outcomes

Percentage of Participants With Best Overall Response (BOR) Based on Physician's Assessment

Time frame: Up to 1 year

Central Contacts

Eisai Inquiry Service

CONTACT

eisai-chiken_hotline@hhc.eisai.co.jp

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.